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Abstract: Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have
mild or moderate courses, up to 5%–10% can have severe, potentially life threatening course, there is an urgent need for effective drugs.
Optimized supportive care remains the mainstay of therapy. There have been more than 300 clinical trials going on, various antiviral
and immunomodulating agents are in various stages of evaluation for COVID-19 in those trials and some of them will be published
in the next couple of months. Despite the urgent need to find an effective antiviral treatment for COVID-19 through randomized
controlled studies, certain agents are being used all over the world based on either in-vitro or extrapolated evidence or observational
studies. The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/
ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as they
have recently been reported to have an activity against SARS-CoV-2 in vitro and are licensed for the treatment of some other human
infections.
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1. Introduction
Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the
COVID-19 patients have mild or moderate course, up
to 5-10% can have severe , potentially life threatening
course, there is an urgent need for effective drugs [1].
Optimized supportive care remains the mainstay of
therapy. As new data regarding clinical characteristics,
treatment options, and outcomes for COVID-19 emerges
approximately every hour, physicians who are in the
care of patients should keep themselves up to date on
this issue. There have been more than 300 clinical trials
going on, and some of them will be published in the next
couple of months. The WHO is launching “Solidarity”
clinical trial for COVID-19 treatments to further
evaluate remdesivir, hydroxychloroquine/chloroquine,
and lopinavir-ritonavir with and without interferon beta1.
Various other antiviral and immunomodulating agents are

in various stages of evaluation for COVID-19. A registry
of international clinical trials can be found on the WHO
website and at ClinicalTrials.gov.
At the moment, it is strongly recommended that
patients be recruited into ongoing trials, which would
provide much-needed evidence on the efficacy and safety
of various therapies for COVID-19, given that we could
not determine whether the benefits outweigh harms for
most treatments [2]2.
Unless used in the context of randomized clinical trials,
antivirals will not be proved to be efficacious or safe for
the treatment of COVID-19. In the 2014 Ebola outbreak,
close to 30, 000 individuals developed Ebola viral disease,
and numerous therapies were tested against this virus,
including chloroquine, hydroxychloroquine, favipiravir,
brincidofovir, monoclonal antibodies, antisense RNA, and
convalescent plasma, among many others. With such a
large number of therapeutic interventions given to affected
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patients, the goal was to determine which was efficacious
against Ebola. Ultimately, none proved to be efficacious
or safe, just because of virtually all studies were singlegroup interventions without concurrent controls, which
led to no definitive conclusion related to efficacy or safety.
This tragedy of not discovering new therapies during an
outbreak should not be repeated [3].
The vast majority of patients with COVID-19 will
do fine without any therapy, so in most cases, there’s no
need for antiviral therapy. However, waiting until patients
are severely ill before initiating therapy could cause us to
miss an early treatment window, during which the disease
course is more modifiable. It is known that antiviral
therapy is most likely to provide benefit when initiated
earlier during the course of the disease both in influenza
[4] and in SARS [5]. Predictors of adverse outcome might
be useful in predicting who will do poorly and thus
who might benefit most from early antiviral therapy3. It
is logical to start antiviral treatment as soon as possible
also for COVID-19 patients especially in the case of the
presence of predictors of adverse outcomes.
Combined usage of antiviral drugs for COVID-19
patients should be considered in the light of current
knowledge and case by case; adverse drug reactions and
drug-drug interactions should always be regarded.
Despite the urgent need to find an effective antiviral
treatment for COVID-19 through randomized controlled
studies, certain agents are being used all over the world
based on either in vitro or extrapolated evidence or
observational studies. The most frequently used agents both
in Turkey and all over the world including chloroquine,
hydroxychloroquine, lopinavir/ritonavir, favipiravir and
remdesivir will be reviewed here4567. Nitazoxanide and
ivermectin were also included in this review as they
have recently been reported to have an activity against
SARS-CoV-2 in vitro and are licensed for the treatment of
some other human infections. Mechanisms of actions of
these drugs were shown in Table.

1.1. Hydroxychloroquine and Chloroquine
Chloroquine (CQ) and hydroxychloroquine (HCQ)
are aminoquinolines, which have been used to treat
malaria and autoimmune diseases for over 50 years.
Besides their antimalarial effects, these two drugs
possess immunomodulatory effects allowing them to
use for the treatment of autoimmune conditions such as
systemic lupus erythematosus and rheumatoid arthritis.
Hydroxychloroquine and chloroquine can inhibit certain
cellular functions and molecular pathways involved in
immune activation [Inhibition of MHC class II expression,
antigen presentation and immune activation (reducing
CD154 expression by T cells); inhibition of production
of various proinflammatory cytokines, such as IL-1, IFNα
and TNF, which can protect against cytokine-mediated
cartilage resorption; interference with Toll-like receptor
7 (TLR7) and TLR9 signaling pathways; interference with
cyclic GMP-AMP (cGAMP) synthase (cGAS) activity]
partly by accumulating in lysosomes and auto phagosomes
of phagocytic cells and changing local pH concentrations
[6]. Chloroquine analogs are weak diprotic bases (can
accept more two protons) and they can penetrate and
concentrate within acidic organelles such as endosomes
and lysosomes which leads to elevated intra-vesicular
pH resulting in prevention of endosome trafficking
and prevents viral fusion into the cell. This mechanism
has translated to the potential role of these drugs in
the treatment of COVID-19. Additionally, studies also
revealed that these drugs interfers with the glycosylation
of ACE-2 receptor which prevents SARS-CoV-2 receptor
binding and subsequent infection. Recent in vitro studies
reported CQ and HCQ effective against SARS-CoV-2
at a multiplicity of infection (MOI) of 0.01 with a 50%
effective concentration (EC50) of 2.71 µM and 4.51 µM
in Vero E6 cells, respectively. At all MOIs (0.01, 0.02, 0.2,
and 0.8), EC50 for CQ (2.71, 3.81, 7.14, and 7.36 μM) was
lower than that of HCQ (4.51, 4.06, 17.31, and 12.96 μM)
[7–9]. In another in vitro analysis, HCQ was found to be
more potent than CQ at inhibiting SARS-CoV-2 and HCQ
sulfate 400 mg given twice daily for 1 day, followed by 200
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Table . Antivirals investigated for the treatment of COVID-19 in clinical trials or in vitro studies.
Group

Inhibitors of viral RNA
polymerase /RNA synthesis

Inhibitors of viral protein
synthesis

Drugs

Mechanism of action

Dosing

Remdesivir (GS-5734)

Adenosine nucleotide analogue, prodrug,
RdRp inhibitor

Day 1: 200mg, IV
Day 2–5 (or 10): 100 mg/day,
IV

Favipiravir

Guanosinenucleotid analogue, prodrug,
RdRp inhibitor

Day 1: 2X1600 mg
Day 2–7 (or 10): 2 × 600 mg/
day

Lopinavir/ritonavir

Protease inhibitor

Day 1–10 (or14):
400mg/100mg × 2/day, orally

Hydroxychloroquine

Increasing endosomal pH required for virus/
cell fusion, as well as interfering with the
glycosylation of cellular receptors of SARSCoV (ACE-2)

Viral entry inhibitors
Chloroquine

Nitazoxanide

Interference with host-regulated pathways
involved in viral replication, amplifying
cytoplasmic RNA sensing and type I IFN
pathways

Ivermectin

Inhibition nuclear import of host and viral
proteins through inhibition of importin 1
heterodimer

Imunomodulators

Day 1–5: 2 × 200 mg/day,
orally
Day 1–5 (or 10): 2 × 500 mg/
day, orally

Modified from “Hoffmann C. Treatment. In: Kamps BS, Hoffmann C, eds. Covid Reference, Edition 2020-2. Website www.covidreference.
com”

mg twice daily for 4 more days is recommended to treat
SARS-CoV-2 infection [10,11].
The use of CQ or HCQ is included in COVID-19
treatment guidelines all over the world but data supporting
this is quite scare. An early report from China suggested
that chloroquine usage was associated with reduced
progression of the disease and decreased duration of
symptoms [12]. However, primary data supporting these
claims have not been published.
In a prospective randomized trial of 30 adults with
COVID-19 in China, 15 patients treated with 400 mg HCQ
+ conventional treatment were compared with 15 patients
treated with conventional treatment only. The proportion
of patients with nasopharyngeal viral clearance at day 7,
mean viral clearance time, temperature normalization and
progression rate in CT
were not found to be different between the groups,
and one patient in the HCQ group progressed to severe
disease [13] .
In another randomized trial of 62 patients with mild
COVID-19 pneumonia without hypoxia reported that the
body temperature recovery time and the cough remission

time were significantly shortened in the HCQ treatment
group. Additionally, HCQ treatment group experienced
more improvement of pneumonia symptoms (80.6%, 25
of 31) compared with the control group (54.8%, 17 of 31).
Notably, all 4 patients progressed to severe illness occurred
in the control group. However, there were 2 patients with
mild adverse reactions in the HCQ treatment group.
But, the trial has not been published in a peer-reviewed
journal, and there are concerns about concomitant cotherapies, baseline differences between the groups, and
lack of blinding or placebo control8.
Other published clinical data on either of these agents
are limited and have methodologic problems. In an openlabel case-control study of 36 adults with COVID-19, use
of HCQ (200 mg three times per day for 10 days) was
associated with a higher rate of undetectable SARS-CoV-2
RNA on nasopharyngeal specimens at day 6 compared
with no specific treatment (70 versus 12.5 %, (P < 0.001).
While the combination of HCQ with azithromycin resulted
in 100% viral clearance in 6 patients, HCQ alone resulted
in %57 clearance in 14 patients (P < 0.001) [14].

Chen Z, Hu J, Zhang Z, Jiang S, Han S et al. (2020). Efficacy of hydrochlroquine in patients with COVID-19: Results of a randomized
trial [online]. Website https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2 [accessed 12 April 2020].
8

613

ŞİMŞEK YAVUZ and ÜNAL / Turk J Med Sci
The same group also published the results of 80
COVID-19 patients receiving a combination of HCQ
and azithromycin. They noted clinical improvement in
all but one 86-year-old patient who died and one 74-yearold patient still in the intensive care unit. A rapid fall of
nasopharyngeal viral load tested by qPCR was noted,
with 83% negative at day 7, and 93% on day 8. Virus
cultures from patient’s respiratory samples were negative
in 97.5% patients on day5 [15]. Both of these studies have
substantial methodological problems that cast doubt on
the conclusions [2]9.
Unfortunately, these studies have resulted in the
massive adoption of the regimen by clinicians worldwide.
There are also increasing concerns about the safety of these
drugs: both medications have been independently shown
to increase the risk for QT interval prolongation, druginduced torsade’s de pointes, and drug induced-sudden
cardiac death [16]10.
In a preliminary safety result of a randomized, doubleblinded, phase IIb clinical trial (CloroCovid-19 Study)
aiming to assess safety and efficacy of two different CQ
dosages as adjunctive therapy of hospitalized patients
with SARS-CoV-2, the high dose CQ arm presented more
QTc > 500 ms (25%), and a trend toward higher lethality
(17%) than the lower dosage in the first recruited 81
patients. Preliminary findings suggest that the higher CQ
dosage (10-day regimen) should not be recommended
for COVID-19 treatment because of its potential safety
hazards. As a result, investigators prematurely halted
patient recruitment to this arm [17].
In another recent study from USA, researchers
reported the change in the QT interval in 84 adult
patients with SARS-CoV-2 infection treated with HCQ/
Azithromycin combination. They reported that QTc
prolonged maximally from baseline between days 3 and 4,
in 30% of patients QTc increased by greater than 40 ms and
in 11% of patients QTc increased to >500 ms, representing
high-risk group for arrhythmia. The development of acute

renal failure but not baseline QTc was a strong predictor of
extreme QTc prolongation11.
Finally, a total of 54 serious cardiac events, 7 sudden
cardiac arrests (4 deaths), 37 prolonged QT and 10
arytmia + syncope have been reported to French National
Pharmacovigilance Agency since the 27th of March 202012.
CQ and HCQ have also been suggested as a candidate
for antiviral prophylaxis against the current COVID-19
pandemic because of its demonstrated mechanisms of
action of preventing viral entry and fusion, evidence of in
vitro efficacy at a clinically achievable dose and high tissue
concentration as well as preliminary clinical evidence of
efficacy as a treatment. But there is also insufficient data
to support this suggestion and these agents should not be
used as prophylactic agents for SARS-CoV-2 except in the
context of a clinical trial13.
There are insufficient data thus far to know
whether HCQ or CQ has a role either in the treatment or in
the prophylaxis of COVID-19. Beside antimalarial drugs
can cause ventricular arrhythmias, QT prolongation, and
other cardiac toxicity, which may pose a particular risk to
critically ill persons. Given these serious potential adverse
effects, the hasty and inappropriate interpretation of the
literature by public leaders has the potential to do serious
harm. For these reasons, it is strongly recommended that
patients should be referred to a clinical trial whenever
possible. Ongoing trials for HCQ are actively recruiting
with hopes to further delineate its role in the treatment
and prophylaxis of COVID-19 [11].
1.2. Favipiravir
Favipiravir
(T-705;
6-fluoro-3-hydroxy-2pyrazinecarboxamide) is an antiviral agent that selectively
and potently inhibits the RNA-dependent RNA
polymerase (RdRp) of RNA viruses. Favipiravir undergoes
an intracellular phosphoribosylation to be an active form,
favipiravir ribofuranosyl-5B-triphosphate (favipiravirRTP), which is recognized as a substrate by RdRp, and
inhibits the RNA polymerase activity. Since the catalytic

International Society of Antimicrobial Chemotherapy (2020). Statement on IJAA paper[online]. Website https://www.isac.world/
news-and-publications/official-isac-statement [accessed 12 April 2020].
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infection: preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study) [online]. Website
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12 April 2020].
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domain of RdRp is conserved among various types of
RNA viruses, this mechanism of action may underpins
a broader spectrum of antiviral activities of favipiravir.
Favipiravir-RTP inhibits RdRp of the influenza virus with
an IC50 of0.022 µg/mL, but does not affect the human
DNA polymerases α, β, γ subunits at up to 100 µg/mL. In
addition to the inhibition of influenza virus, favipiravir
shows inhibitory effects on a wide range of RNA viruses,
such as arena-, bunya-, flavi- and filoviruses causing
hemorrhagic fevers [18, 19]. It has been shown to be
effective in the treatment of influenza and in some extent
Ebola virus disease [19–21]. Genome sequencing of the
2019-nCoV identified the virus as a single-stranded RNA
beta-coronavirus with the RdRp gene similar to those
of SARS-CoV and MERS-CoV. Therefore, favipiravir
is considered as one of the potential candidates for
COVID-19, though confirmed in vitro and preclinical
animal studies are not available yet. In an in-vitro study,
SARS-CoV-2 was inhibited by favipiravir in Vero E6 cells
with an EC50 of 61.88 µMol [14]. But in another study
favipiravir showed no apparent antiviral effect against the
SARS-CoV-2 virus in vitro at concentrations under 100
μML [22].
In an open-label, controlled study of 80 patients
with laboratory-confirmed COVID-19, 35 patients who
received oral favipravir plus interferon (IFN)-α by aerosol
inhalation were compared with 45 patients who received
lopinavir/ritonavir plus IFN-α by aerosol inhalation.
All baseline characteristics were comparable between
the two arms. A shorter viral clearance time was found
for the favipiravir arm versus the control arm [median
(interquartile range, IQR), 4 (2.5–9) d versus 11 (8–13)
d, P < 0.001]. The favipiravir arm also showed significant
improvement in chest imaging compared with the control
arm, with an improvement rate of 91.43% versus 62.22%
(P = 0.004). After adjustment for potential confounders,
the favipiravir arm also showed a significantly higher
improvement rate in chest imaging. Multivariable Cox
regression showed that favipiravir was independently
associated with faster viral clearance [23]. But this article
has been temporarily removed by the publisher and the
reason for the removal of the article has not been specified
yet and rising the suspicion on the results of the study.
In a randomized clinical trial14 120 patients who were
assigned to the favipiravir group compared with 120
arbidol treated patients. In patients with mild-moderate
COVID-19, 7 day’s clinical recovery rate was 55.86% in
the arbidol group and 71.43% in the favipiravir group (P =
0.0199). For mild-moderate COVID-19 patients the time
of fever reduction and cough relief in the favipiravir group
was significantly shorter than that in the arbidol group

(both P < 0.001), no difference was observed of auxiliary
oxygen therapy or noninvasive mechanical ventilation
rate (both P > 0.05). The most possible adverse events
were abnormal liver function tests, psychiatric symptom
reactions, digestive tract reactions and raised serum
uric acid [3 (2.50 %) in arbidol group vs. 16 (13.79%)
in favipiravir group, P < 0.0001]. These trials have not
been published in a peer-reviewed journal, and there
are concerns about concomitant co-therapies, baseline
differences between the groups, and lack of blinding or
placebo control.
At the moment current knowledge is not enough to
recommend favipiravir for the treatment of COVID-19
and additional studies are needed. There are several RCT
going on in China.
1.3. Remdesivir
Remdesivir is a novel antiviral drug developed by Gilead
Sciences, originally for the treatment of Ebola virus disease
and Marburg virus infections. Remdesivir is a prodrug of
a nucleotide analog that is intracellularly metabolized to
an analog of adenosine triphosphate that inhibits viral
RNA polymerases. Remdesivir has broadspectrum activity
against members of several virus families, including
filoviruses (e.g., Ebola) and coronaviruses [e.g., SARSCoV and Middle East respiratory syndrome coronavirus
(MERSCoV)] and has shown prophylactic and therapeutic
efficacy in nonclinical models of these coronaviruses. In
vitro testing has also shown that remdesivir has activity
against SARS-CoV-2 with an EC50 value of 1.76 μM in
Vero E6 cells suggesting its working concentration is
likely to be achieved in nonhuman primate models [8].
Treatment with intravenous remdesivir showed significant
improvement for the first COVID-19 case in US [24] and
then a trial has been initiated quickly to assess the efficacy
and safety of remdesivir in patients hospitalized with
2019-nCoV infection. In a cohort of patients hospitalized
for severe Covid-19 who were treated with compassionate
use remdesivir, clinical improvement was observed in 36
of 53 patients (68%) [25]. As there was no placebo or active
comparator in this study, it is hard to draw any concrete
conclusions and measurement of efficacy will require
results of ongoing randomized, placebo-controlled trials
of remdesivir therapy. There are 4 clinical trials currently
enrolling patients in the United States and, two additional
trials recruiting only in China have been registered on
ClinicalTrials.gov, NCT04257656 (severe disease) and
NCT04252664 (mild-moderate disease) [2].
1.4. Lopinavir/ritonavir( LPV/r)
Lopinavir is a protease inhibitor used to treat HIV
infection, with ritonavir as a booster. Protease is a key

Chen C, Huang J, Cheng Z, Zhang Y, Cheng Z et al. (2020). Favipiravir versus arbidol for COVID-19: a randomized clinical trial
[online]. Website https://www.medrxiv.org/content/medrxiv/early/2020/04/08/2020.03.17.20037432.full.pdf [accessed 12 April 2020].
14

615

ŞİMŞEK YAVUZ and ÜNAL / Turk J Med Sci
enzyme in coronavirus polyprotein processing and
lopinavir and/or ritonavir has anti coronavirus activity
in vitro. Most in vitro studies have shown that SARS‐
CoV could be inhibited by lopinavir and that the EC50
of lopinavir is acceptable. Lopinavir showed an antiviral
effect against SARS-CoV-2 virus in Vero E6 cells with the
estimated EC50 at 26.63 μM [26].
Furthermore, two retrospective matched cohort studies
of SARS patients revealed that LPV/r plays an essential
role in the clinical outcome, especially in the early stage. In
a study from Hong-Kong, compared with ribavirin alone,
patients treated with lopinavir/ritonavir plus ribavirin had
a lower risk of acute respiratory distress syndrome (ARDS)
or death caused by SARS-CoV, 2.4% vs. 28.8%, P = 0.001)
at day 21 after the onset of symptoms [27].
LPV/r treatment alone or in combination with
interferon had improved clinical outcomes in experiments
involving common marmosets and in some MERS patient
[28].
Postexposure prophylaxis with LPV/r was found to
be associated with a 40% decrease in the risk of MERS
infection, although the design of the study was raised
some concerns [29].
Five patients with COVID-19 in Singapore were treated
with LPV/r within 1 to 3 days of desaturation, but evidence
of clinical benefit was equivocal. While defervescence
occurred within 1 to 3 days of LPV/r initiation, it was
unable to prevent progressive disease in 2 patients. A
decline in viral load as indicated by the cycle threshold
value from nasopharyngeal swabs also appeared similar
between those treated and not treated with LPV/r [30].
In another study of of 47 patients with COVID-19;
compared with the standard of care (arbidol plus IFN-α
inhaler) (SOC) (5 patients), the combination treatment
with LPV/r plus SOC (42 patients) has resulted in a shorter
time (test group: 4.8 ± 1.94 days vs. control group: 7.3 ±
1.53 days, P = 0.0364) to return normal body temperature
and to be negative for SARS-CoV-2 test in clinical samples
(7.8 ± 3.09 days vs. 12.0 ± 0.82 days, P = 0.0219) [31].
In another study, 44 patients with mild/moderate
COVID-19 were randomly assigned to receive LPV/r (21
patients), arbidol(16 patients) and no antiviral medication
as control (7 patients). No statistical differences were found
among three groups in the rates of antipyretics, cough
alleviation, improvement of chest CT or the deterioration
rate of clinical status (all P > 0.05). Overall, 5 (23.8%)
patients in the LPV/r group experienced adverse events
during the follow-up period. No apparent adverse events
occurred in the arbidol or control group. It was concluded
from this study that LPV/r or arbidol monotherapy seems

little benefit for improving the clinical outcome of mild/
moderate COVID-19 and LPV/r might lead to more
adverse events15 .
In a randomized trial of 199 patients with severe
COVID-19, the addition of LPV/r (400/100 mg) twice
daily for 14 days to standard care did not decrease the
time to clinical improvement compared with standard
care alone [32]. There was a trend towards decreased
mortality with LPV/r (19 versus 25 percent), and the
numerical difference in mortality was greater among
those who were randomized within 12 days of symptom
onset, but neither difference was statistically significant.
The rate of SARS-CoV-2 decline was similar in the group
that received LPV/r and the group that did not. LPV/r
was stopped early in 14 percent because of adverse effects.
The patients recruited for the study were late in infection
and already had considerable tissue damage (as evidenced
by compromised lung function and 25% mortality in the
control group). Even highly active antibacterial agents
have limited efficacy in advanced bacterial pneumonia
[33]. Accelerated clinical recovery (16.0 days vs. 17.0 days)
and reduced mortality (19.0% vs. 27.1%) were observed in
a post hoc subgroup of those treated within 12 days after
the onset of symptoms, but not in those treated later [48,
49]. Also in another study of 280 COVID-19 patients,
time from illness onset to antiviral was found to be a
risk factor for severe disease. Patients in the mild group
experienced earlier initiation of antiviral treatment (1.19
± 0.45 vs. 2.65 ± 1.06 days in the severe group, P < 0.001)
[34]. The question of whether earlier LPV/r treatment in
COVID-19 could have clinical benefit is an important one
that requires further studies.
With the available data, it is difficult to assess whether
LPV/r has a role for the treatment of COVID-19 either as
monotherapy or in combination, limited data suggesting
no advantage over standard care for SARS-CoV-2.
Importantly, it warrants comment that in the recent
randomized controlled trial in COVID-19 pneumonia the
median time from symptom onset to initiation of therapy
was 13 days, and in the SARS CoV-1 experience therapy
appeared effective if started early, but not as rescue/salvage.
If utilized, drug interactions must be screened and
gastrointestinal toxicities, including diarrhea, nausea,
and vomiting, and hepatoxicity require close monitoring,
particularly since elevated AST or ALT may exclude
patients with COVID-19 from clinical trials.
If LPV/r is used, the patient’s HIV status should be
known and if the patient has HIV, LPV/r should be used
as part of a standard combination antiretroviral regimen.

Li Y, Xie Z, Lin W, Cai W, Wen C, et al. An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir
or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). [online]. Website https://www.medrxiv.org/
content/10.1101/2020.03.19.20038984v2 [accessed 12 April 2020].
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1.5. Nitazoxanide
Nitazoxanide and its active metabolite, tizoxanide have
demonstrated potent in vitro activity against SARS CoV-2
and MERS CoV in Vero E6 cells with an EC50 of 2.12 μM
and 0.92 μM, respectively. It also displays broad-spectrum
in vitro antiviral activity
against influenza, respiratory syncytial virus,
parainfluenza, rotavirus, and norovirus among others in
addition to coronaviruses. This broad-spectrum antiviral
activity is believed to be due to the fact that the mechanism
of action is based on interference with host-regulated
pathways involved in viral replication rather than virusspecific pathways [35]. Nitazoxanideupregulates the innate
antiviral mechanisms by broadly amplifying cytoplasmic
RNA sensing and type I IFN pathways. Nitazoxanide
interferes with the viral infection by upregulating the
precise host mechanisms that viruses target to bypass host
cellular defenses [36]. Due to its broad-spectrum antiviral
activity, nitazoxanide is being investigated in clinical trials
including randomized controlled ones for the management
of influenza and other acute respiratory infections, although
results are not encouraging or unavailable yet. Although
the in vitro activity of nitazoxanide against SARS-CoV-2 is
encouraging, more data are clearly needed to determine its
role in the management of COVID-19 [26]16.
1.6. Ivermectin
Ivermectin is an FDA-approved broad-spectrum
antiparasitic agent that in recent years, it has shown to
have antiviral activity against a broad range of viruses in
vitro. Originally identified as an inhibitor of the interaction
between the human immunodeficiency virus-1 (HIV-1)
integraseprotein and the importin (IMP) 1 heterodimer
responsible for integrase protein nuclear import,

ivermectin has since been confirmed to inhibit integrase
protein nuclear import and HIV-1 replication. Other
actions of ivermectin have been reported, but ivermectin
has been shown to inhibit the nuclear import of host and
viral proteins. It has been demonstrated to limit infection
by some RNA viruses including influenza, dengue and West
Nile viruses. Ivermectin has similarly been shown to be
effective against the DNA virus pseudorabies virus (PRV)
both in vitro and in vivo, with ivermectin treatment shown
to increase survival in PRV-infected mice [37]. Efficacy was
not observed for ivermectin against Zikavirus in mice, but
the authors acknowledged that study limitations justified
the reevaluation of ivermectin’s anti-Zika virus activity
[38]. Finally, ivermectin was the focus of a phase III clinical
trial in Thailand in 2014–2017, against dengue virus
infection, in which a single daily oral dose was observed
to be safe and resulted in a significant reduction in serum
levels of viral NS1 protein, but no change in viremia or
clinical benefit was observed17.
In an in vitro study, ivermectin was found to be an
inhibitor of the SARS-CoV-2, with a single addition to
Vero-hSLAM cells 2 h post infection with SARS-CoV-2
able to effect ~5000-fold reduction in viral RNA at 48 h.
Authors hypothesize that this was likely through inhibiting
IMPα/β1- mediated nuclear import of viral proteins (as
shown for other RNA viruses) and this inhibition disrupts
the immune evasion mechanism of virus [38]. Further in
vitro, in vivo and clinical trials are needed to determine its
role in the management of COVID-19.
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